Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials

ConclusionsBased on the current evidence, 0.75 and 1.5  mg dulaglutide are associated with better glycemic control and lower rate of hypoglycemia in patients with T2DM.
Source: Endocrine - Category: Endocrinology Source Type: research